NR1H4 and metabolic dysfunction-associated steatohepatitis: In patients with NASH, elevated serum levels of bile acids, particularly the FXR antagonist deoxycholic acid, and reduced levels of the agonist chenodeoxycholic acid lead to suppressed FXR signaling [65].